Scope
The 2025 ACG guideline links high-quality gastric endoscopy and compartment-specific histology to risk-stratified surveillance, H. pylori eradication and expert treatment of dysplasia. Many surveillance choices are conditional because evidence is limited. US population-screening recommendations and demographic risk categories should be distinguished from an individual patient’s clinical risk in India.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Distinguish population screening from individual risk
- ACG suggests against routine upper-endoscopic gastric cancer screening in the general US population. It cannot recommend for or against opportunistic endoscopy solely on immigration, race or environmental risk because direct US evidence is insufficient. [1]
- For a first-degree family history of gastric cancer, individualized discussion may include endoscopic screening and H. pylori eradication. The key concept proposes starting at age 45–60 or 10 years before the youngest affected relative’s diagnosis. [1]
- Do not substitute noninvasive biomarkers for gastric premalignant-condition or cancer screening and surveillance in the US framework; ACG conditionally advises against this use. [1]
Obtain a high-quality examination and informative histology
- Perform careful gastric inspection with cleansing, adequate insufflation, systematic visual mapping, landmark and abnormality photographs, and adequate inspection time. [1]
- For suspected premalignant disease, ACG suggests high-definition white-light plus image-enhanced endoscopy rather than relying on standard inspection alone. [1]
- In increased-risk patients or suspected premalignant disease or cancer, use systematic updated Sydney-protocol sampling. Keep antrum/incisura and corpus samples in separate containers and targeted abnormalities in additional containers. [1]
- Ask pathology to report intestinal-metaplasia subtype, severity and anatomical extent. Distinguish complete, incomplete and mixed subtypes; antrum/incisura-only disease is limited, whereas corpus involvement is extensive. [1]
Use histology and clinical risk to select surveillance
- ACG suggests 3-year endoscopic surveillance for intestinal metaplasia with incomplete histology or corpus extension. Metaplasia plus a first-degree family history, emigration from a high-incidence nation or a listed high-risk US racial or ethnic group also qualifies. [1]
- The guideline separately suggests 3-year surveillance for moderate-to-severe intestinal metaplasia or atrophic gastritis in antral or corpus biopsies. [1]
- For low-risk disease, ACG suggests against surveillance: examples are complete, focal antral metaplasia without high-risk clinical features and mild atrophic gastritis. Establish subtype, distribution and risk before applying this category. [1]
- Do not routinely repeat endoscopy within 12 months merely to risk-stratify nondysplastic premalignant disease, unless examination quality or Sydney-protocol sampling was inadequate. Multiple risk factors can justify an individualized interval shorter than 3 years. [1]
Confirm and treat dysplastic lesions with expertise
- For indefinite, low-grade or high-grade dysplasia with visible margins, ACG suggests endoscopic resection when clinically appropriate. If margins are not visible, repeat high-definition and image-enhanced evaluation with an experienced endoscopist. [1]
- Refer suitable dysplasia-resection candidates, particularly for endoscopic submucosal dissection, to a high-volume centre with gastric-neoplasia diagnostic and therapeutic expertise. [1]
- After confirmed complete dysplasia resection, perform surveillance with an experienced endoscopist, high-definition white-light and image-enhanced imaging, systematic biopsies and targeted sampling. [1]
Address H. pylori and autoimmune gastritis
- Eradicate H. pylori in atrophic gastritis, intestinal metaplasia or dysplasia and after resected early gastric cancer, to reduce progression or metachronous cancer risk. [1]
- Do not prescribe aspirin, NSAIDs, COX-2 inhibitors or antioxidants solely for gastric cancer chemoprevention in premalignant conditions; the recommendation against this use is conditional. [1]
- In autoimmune gastritis, assess H. pylori with a nonserological test, treat positive infection and confirm eradication after treatment. [1]
- Surveillance for autoimmune gastritis requires individual discussion: evidence does not support a fixed formal schedule, although type 1 neuroendocrine-tumour risk and possible gastric cancer risk may justify surveillance. [1]
Manage gastric epithelial polyps according to histology
- Resect gastric adenomas regardless of size to exclude or prevent dysplasia and early cancer; refer for surgery when endoscopic resection is unsuitable and surgery is clinically appropriate. [1]
- For gastric epithelial polyps other than fundic-gland polyps, obtain systematic biopsies of surrounding mucosa. Hyperplastic polyps above 10 mm have no blanket resection recommendation: choose resection or biopsy individually, with consideration of surveillance within 12 months. [1]
Limitations and use
- The guideline is framed for US practice; its population-screening policy and racial or immigration risk categories are not an Indian screening programme.
- Hereditary gastric-cancer syndromes, cardia intestinal metaplasia, MALT lymphoma and definitive gastric-cancer treatment are outside this summary.
- Post-resection surveillance intervals and technical resection pathways require individualized expert assessment; no complete H. pylori drug regimen is supplied.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Diagnosis and Management of Gastric Premalignant Conditions
Selected recommendation material consulted
Publication details
- Issuing organisation
- ACG
- Resource type
- Clinical guideline · House clinical summary
Earlier House summaries: gastric premalignant conditions acg
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.